Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
E-pub ahead of print

Real-life data on treatment and outcomes in advanced ovarian cancer: An observational, multinational cohort study (RESPONSE trial)

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. miRNA Expression in Ovarian Cancer in Fresh Frozen, Formalin-fixed Paraffin-embedded and Plasma Samples

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Preoperative predictors of inguinal lymph node metastases in vulvar cancer - A nationwide study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Defining Substantial Lymphovascular Space Invasion in Endometrial Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Substantial Lymphovascular Space Invasion Is an Adverse Prognostic Factor in High-risk Endometrial Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Identification of Stably Expressed Reference microRNAs in Epithelial Ovarian Cancer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • Christian Marth
  • Miguel Henriques Abreu
  • Klaus Kaae Andersen
  • Karoliina M Aro
  • Maria de Lurdes Batarda
  • Dorry Boll
  • Anne Weng Ekmann-Gade
  • Ulla-Maija Haltia
  • Jesper Hansen
  • Ala Jabri Haug
  • Claus Høgdall
  • Jacob Korach
  • Heini Lassus
  • Kristina Lindemann
  • Els Van Nieuwenhuysen
  • Petronella B Ottevanger
  • Stephan Polterauer
  • Tine Henrichsen Schnack
Vis graf over relationer

BACKGROUND: This study aimed to describe the treatment strategies and outcomes for women with newly diagnosed advanced high-grade serous or endometrioid ovarian cancer (OC).

METHODS: This observational study collected real-world medical record data from eight Western countries on the diagnostic workup, clinical outcomes, and treatment of adult women with newly diagnosed advanced (Stage III-IV) high-grade serous or endometrioid OC. Patients were selected backward in time from April 1, 2018 (the index date), with a target of 120 patients set per country, followed for ≥20 months.

RESULTS: Of the 1119 women included, 66.9% had Stage III disease, 11.7% had a deleterious BRCA mutation, and 26.6% received bevacizumab; 40.8% and 39.3% underwent primary debulking surgery (PDS) and interval debulking surgery (IDS), respectively. Of the patients who underwent PDS, 55.5% had no visible residual disease (VRD); 63.9% of the IDS patients had no VRD. According to physician-assessed responses (at the first assessment after diagnosis and treatment), 53.2% of the total population had a complete response and 25.7% had a partial response to first-line chemotherapy after surgery. After ≥20 months of follow-up, 32.9% of the patients were disease-free, 46.4% had progressive disease, and 20.6% had died. Bevacizumab use had a significant positive effect on overall survival (hazard ratio [HR], 0.62; 95% CI, 0.42-0.91; p = .01). A deleterious BRCA status had a significant positive effect on progression-free survival (HR, 0.60; 95% CI, 0.41-0.84; p < .01).

CONCLUSIONS: Women with advanced high-grade serous or endometrioid OC have a poor prognosis. Bevacizumab use and a deleterious BRCA status were found to improve survival in this real-world population.

LAY SUMMARY: Patients with advanced (Stage III or IV) ovarian cancer (OC) have a poor prognosis. The standard treatment options of surgery and chemotherapy extend life beyond diagnosis for 5 years or more in only approximately 45% of patients. This study was aimed at describing the standard of care in eight Western countries and estimating how many patients who are diagnosed with high-grade serous or endometrioid OC could potentially be eligible for first-line poly(adenosine diphosphate ribose) polymerase inhibitor (PARPi) maintenance therapy. The results highlight the poor prognosis for these patients and suggest that a significant proportion (79%) would potentially be eligible for first-line PARPi maintenance treatment.

OriginalsprogEngelsk
TidsskriftCancer
ISSN0008-543X
DOI
StatusE-pub ahead of print - 17 jun. 2022

Bibliografisk note

© 2022 The Authors. Cancer published by Wiley Periodicals LLC on behalf of American Cancer Society.

ID: 78877329